EP0584251A4 - Molecules ciblees sur un recepteur de cytokine par le traitement de la croissance de cellules neoplasiques. - Google Patents
Molecules ciblees sur un recepteur de cytokine par le traitement de la croissance de cellules neoplasiques.Info
- Publication number
- EP0584251A4 EP0584251A4 EP92912726A EP92912726A EP0584251A4 EP 0584251 A4 EP0584251 A4 EP 0584251A4 EP 92912726 A EP92912726 A EP 92912726A EP 92912726 A EP92912726 A EP 92912726A EP 0584251 A4 EP0584251 A4 EP 0584251A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- meoplastic
- treatment
- cell growth
- cytokine receptor
- targeted molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000010261 cell growth Effects 0.000 title 1
- 102000003675 cytokine receptors Human genes 0.000 title 1
- 108010057085 cytokine receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70193291A | 1991-05-17 | 1991-05-17 | |
US701932 | 1991-05-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0584251A1 EP0584251A1 (fr) | 1994-03-02 |
EP0584251A4 true EP0584251A4 (fr) | 1995-08-02 |
Family
ID=24819258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92912726A Withdrawn EP0584251A4 (fr) | 1991-05-17 | 1992-05-15 | Molecules ciblees sur un recepteur de cytokine par le traitement de la croissance de cellules neoplasiques. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0584251A4 (fr) |
JP (1) | JPH06507900A (fr) |
CA (1) | CA2103258A1 (fr) |
WO (1) | WO1992020364A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4079461B2 (ja) * | 1994-12-29 | 2008-04-23 | 中外製薬株式会社 | Il−6アンタゴニストを含んでなる抗腫瘍剤の作用増強剤 |
EP1185304A2 (fr) * | 1999-06-03 | 2002-03-13 | Bioinnovation Limited | Produits de therapie genique |
KR20050086628A (ko) | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001004A1 (fr) * | 1989-07-06 | 1991-01-24 | Seragen, Inc. | Molecules hybrides |
WO1991002000A1 (fr) * | 1989-08-02 | 1991-02-21 | Seragen, Inc. | Mutants de il-2 a action deletive |
WO1991019745A1 (fr) * | 1990-06-13 | 1991-12-26 | The University Hospital | Toxines chimeriques a geometrie inter-domaine amelioree |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082927A (en) * | 1986-09-24 | 1992-01-21 | The United States Of America As Represented By The Department Of Health And Human Services | Selectively cytotoxic IL-4-PE40 fusion protein |
US5084556A (en) * | 1987-10-23 | 1992-01-28 | Genetics Institute, Inc. | Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
-
1992
- 1992-05-15 WO PCT/US1992/004093 patent/WO1992020364A1/fr not_active Application Discontinuation
- 1992-05-15 JP JP5500214A patent/JPH06507900A/ja active Pending
- 1992-05-15 EP EP92912726A patent/EP0584251A4/fr not_active Withdrawn
- 1992-05-15 CA CA002103258A patent/CA2103258A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001004A1 (fr) * | 1989-07-06 | 1991-01-24 | Seragen, Inc. | Molecules hybrides |
WO1991002000A1 (fr) * | 1989-08-02 | 1991-02-21 | Seragen, Inc. | Mutants de il-2 a action deletive |
WO1991019745A1 (fr) * | 1990-06-13 | 1991-12-26 | The University Hospital | Toxines chimeriques a geometrie inter-domaine amelioree |
Non-Patent Citations (7)
Title |
---|
BACHA, PATRICIA A. ET AL: "Impact of interleukin -2- receptor -targeted cytotoxins on a unique model of murine interleukin -2- receptor -expressing malignancy", INT. J. CANCER (1991), 49(1), 96-101 CODEN: IJCNAW;ISSN: 0020-7136 * |
C. F. LEMAISTRE ET AL.: "PHASE I-II EVALUATION OF AN IL-2 RECEPTOR TARGETED FUSION TOXIN DAB-486 IL-2 FOR TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA.", ISITITUTO SUP. DI SANITA. VII INTERNATIONAL CONFERENCE ON AIDS: SCIENCE CHALLENGING AIDS; FLORENCE, ITALY, 16 June 1991 (1991-06-16), pages 79 * |
CHARLES F. LEMAISTRE ET AL.: "THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA.", LANCET THE, vol. 337, 11 May 1991 (1991-05-11), LONDON GB, pages 1124 - 1125 * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; * |
NICHOLS, J. C. ET AL: "Development of IL-2-toxin ( DAB486 -IL-2) for human clinical trials in interleukin -2 receptor positive malignancies", ZENTRALBL. BAKTERIOL., SUPPL. (1990), 19(BACT. PROTEIN TOXINS), 479-87 CODEN: ZBASE2 * |
See also references of WO9220364A1 * |
TESUYUKI KIYOKAWA ET AL.: "PROTEIN ENGEERING OF DIPHTERIA-TOXIN-RELATED INTERLEUKIN-2 FUSION TOXINS TO INCREASE CYTOTOXIC POTENCY FOR HIGH-AFFINITY IL-2-RECEPTOR-BEARING TARGET CELLS.", PROTEIN ENGINEERING, vol. 4, no. 4, ENGLAND GB, pages 463 - 468 * |
Also Published As
Publication number | Publication date |
---|---|
CA2103258A1 (fr) | 1992-11-18 |
JPH06507900A (ja) | 1994-09-08 |
EP0584251A1 (fr) | 1994-03-02 |
WO1992020364A1 (fr) | 1992-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0603194A4 (fr) | Molecules ciblees sur un recepteur du facteur de croissance epidermique, et utilisees dans le traitement de l'arthrite inflammatoire. | |
EP0721340A4 (fr) | Utilisation de molecules ciblees sur des recepteurs de surface de cellules pour le traitement des maladies virales | |
EP0576870A3 (fr) | Appareil pour la culture de micro-organismes. | |
EP0639362A3 (fr) | Article absorbant adaptable à la croissance. | |
HU9300252D0 (en) | Structure for supporting vertebra | |
AU7344291A (en) | Spine tensioning body support | |
EP0668774A4 (fr) | Molecules ciblees sur un recepteur de l'interleukine destinees a traiter l'arthrite inflammatoire. | |
GB8728550D0 (en) | Adjustable chair | |
GB9104021D0 (en) | Adjustable pot-plant support | |
EP0584251A4 (fr) | Molecules ciblees sur un recepteur de cytokine par le traitement de la croissance de cellules neoplasiques. | |
ZA935154B (en) | Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions | |
PH31659A (en) | Therapeutic nucleotides. | |
AU2593692A (en) | Biological wastewater treatment process | |
EP0609358A4 (fr) | Procedes de traitement de l'hyperlipidemie consistant a utiliser des azaspiranes. | |
AU2959892A (en) | Apparatus for thermal treatment of the prostate | |
PL306798A1 (en) | Biologically active ureide derivatives useful in treating disease being breed by lentivirus | |
ZA925385B (en) | Seed treatment | |
GB9027429D0 (en) | Effluent treatment | |
AU2518592A (en) | Mutated growth factor receptor as medicament and its use for treating cancer | |
GB9225791D0 (en) | Adjustable chair bed | |
IL103451A0 (en) | Adjustable orthotic | |
GB9108786D0 (en) | Effluent treatment | |
GB8716041D0 (en) | Adjustable chair | |
AU2801092A (en) | Drugs for treating aids | |
AU2048592A (en) | Seed treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19950615 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19970402 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19971014 |